retatrutide type 2 diabetes trial results Weight loss with as compared to licenced obesity Triple hormone receptor agonist retatrutide

By replicating GLP-1s natural activity, Ozempic reduces appetite, increases satiety (the feeling of fullness), and helps control food intake

Send questions or comments to [email protected]

(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers

That matters because the promise of losing this much weight is that the heart benefits too

If more than 5 days have passed, skip the missed dose altogether and take your next dose on the regularly scheduled day

BOOK A CONSULTATION(opens in a new tab) Lets take a closer look at what GLP-1 medications are and how they might help you finally reach your health goals